SEGMENTS

12 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

SEGMENTS

8. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI, consisting of patent maintenance costs.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not have any revenues or activities other than patent maintenance. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Fiscal Years Ended March 31,
	2022			2021
Revenues:
Aethlon	$	294,165		$	659,104
ESI		–			–
Total Revenues	$	294,165		$	659,104
Operating Losses:
Aethlon	$	(10,396,914	)	$	(7,867,547	)
ESI		(23,971	)		(23,952	)
Total Operating Loss	$	(10,420,885	)	$	(7,891,499	)
Net Losses:
Aethlon	$	(10,396,914	)	$	(7,867,547	)
ESI		(23,971	)		(23,952	)
Net Loss Before Non-Controlling Interests	$	(10,420,885	)	$	(7,891,499	)
Cash:
Aethlon	$	17,072,222		$	9,861,378
ESI		197			197
Total Cash	$	17,072,419		$	9,861,575
Total Assets:
Aethlon	$	19,417,757		$	10,668,719
ESI		197			197
Total Assets	$	19,417,954		$	10,668,916
Depreciation and Amortization:
Aethlon	$	123,685		$	39,939
ESI		–			–
Total Depreciation and Amortization	$	123,685		$	39,939
Capital Expenditures:
Aethlon	$	349,193		$	59,881
ESI		–			–
Capital Expenditures	$	349,193		$	59,881